Abstract
The PI3K/AKT/mTOR pathway is frequently activated in various human cancers and has been considered a promising therapeutic target. Many of the positive regulators of the PI3K/AKT/mTOR axis, including the catalytic (p110α) and regulatory (p85α), of class IA PI3K, AKT, RHEB, mTOR, and eIF4E, possess oncogenic potentials, as demonstrated by transformation assays in vitro and by genetically engineered mouse models in vivo. Genetic evidences also indicate their roles in malignancies induced by activation of the upstream oncoproteins including receptor tyrosine kinases and RAS and those induced by the loss of the negative regulators of the PI3K/AKT/mTOR pathway such as PTEN, TSC1/2, LKB1, and PIPP. Possible mechanisms by which the PI3K/AKT/mTOR axis contributes to oncogenic transformation include stimulation of proliferation, survival, metabolic reprogramming, and invasion/metastasis, as well as suppression of autophagy and senescence. These phenotypic changes are mediated by eIF4E-induced translation of a subset of mRNAs and by other downstream effectors of mTORC1 including S6K, HIF-1α, PGC-1α, SREBP, and ULK1 complex.
This is a preview of subscription content, log in via an institution to check access.
References
Adams JR, Xu K, Liu JC et al (2011) Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res 71:2706–2717. doi:10.1158/0008-5472.CAN-10-0738
Amzel LM, Huang CH, Mandelker D et al (2008) Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 8:665–669. doi:10.1038/nrc2443
Angulo I, Vadas O, Garçon F et al (2013) Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 342:866–871. doi:10.1126/science.1243292
Aoki M (2000) The Catalytic Subunit of Phosphoinositide 3-Kinase: Requirements for Oncogenicity. J Biol Chem 275:6267–6275. doi:10.1074/jbc.275.9.6267
Aoki M, Batista O, Bellacosa A et al (1998) The Akt kinase: Molecular determinants of oncogenicity. Proc Natl Acad Sci 95:14950–14955. doi:10.1073/pnas.95.25.14950
Aoki M, Blazek E, Vogt PK (2001) A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 98:136–141. doi:10.1073/pnas.011528498
Arteaga CL (2010) Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. Curr Top Microbiol Immunol 347:189–208. doi:10.1007/82_2010_54
Avdulov S, Li S, Michalek V et al (2004) Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5:553–563. doi:10.1016/j.ccr.2004.05.024
Baer R, Cintas C, Dufresne M et al (2014) Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α Genes Dev 28:2621–2635. doi:10.1101/gad.249409.114
Banerji S, Cibulskis K, Rangel-Escareno C et al (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486:405–409. doi:10.1038/nature11154
Bellacosa A, Testa JR, Staal SP, Tsichlis PN (1991) A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254:274–277. doi:10.1126/science.1833819
Ben-Sahra I, Howell JJ, Asara JM, Manning BD (2013) Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339:1323–1328. doi:10.1126/science.1228792
Ben-Sahra I, Hoxhaj G, Ricoult SJH et al (2016) mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 351:728–733. doi:10.1126/science.aad0489
Bhat M, Robichaud N, Hulea L et al (2015) Targeting the translation machinery in cancer. Nat Rev Drug Discov 14:261–278. doi:10.1038/nrd4505
Blanco-Aparicio C, Pérez-Gallego L, Pequeño B et al (2007) Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis 28:584–594. doi:10.1093/carcin/bgl190
Bunney TD, Katan M (2010) Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 10:342–352. doi:10.1038/nrc2842
Burke JE, Perisic O, Masson GR et al (2012) Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci U S A 109:15259–15264. doi:10.1073/pnas.1205508109
Cai SL, Tee AR, Short JD et al (2006) Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 173:279–289. doi:10.1083/jcb.200507119
Cai W, Ye Q, She Q-B (2014) Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail. Oncotarget 5:6015–6027. doi:10.18632/oncotarget.2109
Carpten JD, Faber AL, Horn C et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439–444. doi:10.1038/nature05933
Castellano E, Sheridan C, Thin MZ et al (2013) Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 24:617–630. doi:10.1016/j.ccr.2013.09.012
Chang HW (1997) Transformation of Chicken cells by the gene encoding the catalytic subunit of PI 3-Kinase. Science 276:1848–1850. doi:10.1126/science.276.5320.1848
Charles R-P, Silva J, Iezza G et al (2014) Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis. Mol Cancer Res 12:979–986. doi:10.1158/1541-7786.MCR-14-0158-T
Chen M, Pratt CP, Zeeman ME et al (2011) Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 20:173–186. doi:10.1016/j.ccr.2011.07.013
Chen ML, Xu PZ, Peng XD et al (2006) The deficiency of Akt1 is sufficient to suppress tumor development in Pten± mice. Genes Dev 20:1569–1574. doi:10.1101/gad.1395006
Cheung LWT, Hennessy BT, Li J et al (2011) High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 1:170–185. doi:10.1158/2159-8290.CD-11-0039
Clegg NJ, Couto SS, Wongvipat J et al (2011) MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS ONE. doi:10.1371/journal.pone.0017449
Collisson EA, Trejo CL, Silva JM et al (2012) A Central role for RAF → MEK → ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2:685–693. doi:10.1158/2159-8290.CD-11-0347
Coulter TI, Chandra A, Bacon CM et al (2017) Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study. J Allergy Clin Immunol 139(597–606):e4. doi:10.1016/j.jaci.2016.06.021
Cristofano AD, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19:348–355. doi:10.1038/1235
Csibi A, Fendt S-M, Li C et al (2013) The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153:840–854. doi:10.1016/j.cell.2013.04.023
Cunningham JT, Rodgers JT, Arlow DH et al (2007) mTOR controls mitochondrial oxidative function through a YY1-PGC-1α transcriptional complex. Nature 450:736–740. doi:10.1038/nature06322
Dazert E, Hall MN (2011) mTOR signaling in disease. Curr Opin Cell Biol 23:744–755. doi:10.1016/j.ceb.2011.09.003
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11–20. doi:10.1016/j.cmet.2007.10.002
Deming DA, Leystra AA, Farhoud M et al (2013) mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers. PLoS ONE. doi:10.1371/journal.pone.0060709
Deming DA, Leystra AA, Nettekoven L et al (2014) PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene 33:2245–2254. doi:10.1038/onc.2013.167
Denley A, Kang S, Karst U, Vogt PK (2008) Oncogenic signaling of class I PI3K isoforms. Oncogene 27:2561–2574. doi:10.1038/sj.onc.1210918
Denley A, Gymnopoulos M, Kang S et al (2009) Requirement of phosphatidylinositol(3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. Mol Cancer Res 7:1132–1138. doi:10.1158/1541-7786.MCR-09-0068
Deuker MM, Durban VM, Phillips WA, McMahon M (2015) PI3′-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov 5:143–153. doi:10.1158/2159-8290.CD-14-0856
Dillon RL, Marcotte R, Hennessy BT et al (2009) Akt1 and Akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 69:5057–5064. doi:10.1158/0008-5472.CAN-08-4287
Dodd KM, Yang J, Shen MH et al (2015) mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34:2239–2250. doi:10.1038/onc.2014.164
Durban VM, Deuker MM, Bosenberg MW et al (2013) Differential AKT dependency displayed by mouse models of BRAF V600E-Initiated melanoma. J Clin Invest 123:5104–5118. doi:10.1172/JCI69619
Düvel K, Yecies JL, Menon S et al (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39:171–183. doi:10.1016/j.molcel.2010.06.022
Dzneladze I, He R, Woolley JF et al (2015) INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. Leukemia 29:1485–1495. doi:10.1038/leu.2015.51
Edinger AL, Thompson CB (2004) An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival. Oncogene 23:5654–5663. doi:10.1038/sj.onc.1207738
Elghazi L, Weiss AJ, Barker DJ et al (2009) Regulation of pancreas plasticity and malignant transformation by Akt signaling. Gastroenterology 136(1091–1103):e8. doi:10.1053/j.gastro.2008.11.043
Engelman JA, Chen L, Tan X et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351–1356. doi:10.1038/nm.1890
Eser S, Reiff N, Messer M et al (2013) Selective requirement of PI3K/PDK1 signaling for kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23:406–420. doi:10.1016/j.ccr.2013.01.023
Fedele CG, Ooms LM, Ho M et al (2010) Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A 107:22231–22236. doi:10.1073/pnas.1015245107
Feldman ME, Shokat KM (2010) New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of tor kinase domain inhibitors (TORKinibs). Curr Top Microbiol Immunol 347:241–262. doi:10.1007/82-2010-64
Franco I, Gulluni F, Campa CC et al (2014) PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. Dev Cell 28:647–658. doi:10.1016/j.devcel.2014.01.022
Fruman DA, Meyers RE, Cantley LC (1998) Phosphoinositide kinases. Annu Rev Biochem 67:481–507. doi:10.1146/annurev.biochem.67.1.481
Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:140–156. doi:10.1038/nrd4204
Furic L, Rong L, Larsson O et al (2010) eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A 107:14134–14139. doi:10.1073/pnas.1005320107
Furman RR, Sharman JP, Coutre SE et al (2014) Idelalisib and Rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997–1007. doi:10.1056/NEJMoa1315226
Ganley IG, Lam DH, Wang J et al (2009) ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem 284:12297–12305. doi:10.1074/jbc.M900573200
Gao T, Furnari F, Newton AC (2005) PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18:13–24. doi:10.1016/j.molcel.2005.03.008
Gasser JA, Inuzuka H, Lau AW et al (2014) SGK3 mediates INPP4B-Dependent PI3K signaling in breast cancer. Mol Cell 56:595–607. doi:10.1016/j.molcel.2014.09.023
Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892. doi:10.1056/NEJMoa1113205
Gewinner C, Wang ZC, Richardson A et al (2009) Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16:115–125. doi:10.1016/j.ccr.2009.06.006
Gopal AK, Kahl BS, de Vos S et al (2014) PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370:1008–1018. doi:10.1056/NEJMoa1314583
Grabiner BC, Nardi V, Birsoy K et al (2014) A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 4:554–563. doi:10.1158/2159-8290.CD-13-0929
Graff JR, Zimmer SG (2003) Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 20:265–273
Green S, Trejo CL, McMahon M (2015) PIK3CAH1047R accelerates and enhances KRASG12D-driven lung tumorigenesis. Cancer Res 75:5378–5391. doi:10.1158/0008-5472.CAN-15-1249
Gritsman K, Yuzugullu H, Von T et al (2014) Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. J Clin Invest 124:1794–1809. doi:10.1172/JCI69927
Guertin DA, Stevens DM, Saitoh M et al (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15:148–159. doi:10.1016/j.ccr.2008.12.017
Gulhati P, Bowen KA, Liu J et al (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 71:3246–3256. doi:10.1158/0008-5472.CAN-10-4058
Guo ST, Chi MN, Yang RH, et al (2015) INPP4B is an oncogenic regulator in human colon cancer. Oncogene 1–13. doi:10.1038/onc.2015.361
Gupta S, Ramjaun AR, Haiko P et al (2007) Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 129:957–968. doi:10.1016/j.cell.2007.03.051
Gwinn DM, Shackelford DB, Egan DF et al (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214–226. doi:10.1016/j.molcel.2008.03.003
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013
Hao Y, Wang C, Cao B et al (2013) Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell 23:583–593. doi:10.1016/j.ccr.2013.03.021
Hare LM, Phesse TJ, Waring PM et al (2014) Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice. Biochem J 458:251–258. doi:10.1042/BJ20131412
Hollander MC, Blumenthal GM, Dennis PA (2011a) PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11:289–301. doi:10.1038/nrc3085
Hollander MC, Maier CR, Hobbs EA et al (2011b) Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene 30:1812–1821. doi:10.1038/onc.2010.556
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714–726. doi:10.1038/nrc3599
Hon WC, Berndt A, Williams RL (2012) Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Oncogene 31:3655–3666. doi:10.1038/onc.2011.532
Hsieh AC, Costa M, Zollo O et al (2010) Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17:249–261. doi:10.1016/j.ccr.2010.01.021
Hsieh AC, Liu Y, Edlind MP et al (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55–61. doi:10.1038/nature10912
Huang C-H, Mandelker D, Schmidt-Kittler O et al (2007) The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations. Science 318:1744–1748. doi:10.1126/science.1150799
Huang J, Manning BD (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412:179–190. doi:10.1042/BJ20080281
Hudson CC, Liu M, Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004–7014. doi:10.1128/MCB.22.20.7004
Hutchinson J, Jin J, Cardiff RD et al (2001) Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21:2203–2212. doi:10.1128/MCB.21.6.2203-2212.2001
Hutchinson JN, Jin J, Cardiff RD et al (2004a) Activation of Akt-1 (PKB-α) Can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion activation of Akt-1 (PKB-␣) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. 1:3171–3178
Hutchinson JN, Jin J, Cardiff RD et al (2004b) Activation of Akt-1 (PKB-α) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res 64:3171–3178. doi:10.1158/0008-5472.can-03-3465
Iglesias-Bartolome R, Patel V, Cotrim A et al (2012) MTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell 11:401–414. doi:10.1016/j.stem.2012.06.007
Ikenoue T (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65:4562–4567. doi:10.1158/0008-5472.CAN-04-4114
Inoki K, Li Y, Zhu T et al (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648–657. doi:10.1038/ncb839
Inoki K, Zhu T, Guan K-L (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590 (S0092867403009292 [pii])
Isakoff SJ, Engelman JA, Irie HY et al (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65:10992–11000. doi:10.1158/0008-5472.CAN-05-2612
Jaiswal BS, Janakiraman V, Kljavin NM et al (2009) Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation. Cancer Cell 16:463–474. doi:10.1016/j.ccr.2009.10.016
Jia S, Gao X, Lee SH et al (2013) Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3:44–51. doi:10.1158/2159-8290.CD-12-0262
Jia S, Liu Z, Zhang S et al (2008) Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 454:776–779. doi:10.1038/nature07091
Jiang H, Vogt PK (2008) Constitutively active Rheb induces oncogenic transformation. Oncogene 27:5729–5740. doi:10.1038/onc.2008.180
Jiang L, Xu L, Mao J et al (2013) Rheb/mTORC1 signaling promotes kidney fibroblast activation and fibrosis. J Am Soc Nephrol 24:1114–1126. doi:10.1681/ASN.2012050476
Joshi A, Miller C, Baker SJ, Ellenson LH (2015) Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion. Am J Pathol 185:1104–1113. doi:10.1016/j.ajpath.2014.12.019
Jung CH, Jun CB, Ro S-H et al (2009) ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 20:1992–2003. doi:10.1091/mbc.E08-12-1249
Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102:802–807. doi:10.1073/pnas.0408864102
Kang S, Denley A, Vanhaesebroeck B, Vogt PK (2006) Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 103:1289–1294. doi:10.1073/pnas.0510772103
Kim J, Kundu M, Viollet B, Guan K-L (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13:132–141. doi:10.1038/ncb2152
Kinross KM, Montgomery KG, Kleinschmidt M et al (2012) An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 122:553–557. doi:10.1172/JCI59309
Kobayashi T, Minowa O, Kuno J et al (1999) Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 59:1206–1211
Kobayashi T, Minowa O, Sugitani Y et al (2001) A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci U S A 98:8762–8767. doi:10.1073/pnas.151033798
Koren S, Reavie L, Couto JP et al (2015) PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature 525:114–118. doi:10.1038/nature14669
Korsse SE, Peppelenbosch MP, Van Veelen W (2013) Targeting LKB1 signaling in cancer. Biochim Biophys Acta - Rev Cancer 1835:194–210. doi:10.1016/j.bbcan.2012.12.006
Lamouille S, Derynck R (2007) Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178:437–451. doi:10.1083/jcb.200611146
Laplante M, Sabatini DM (2012) MTOR signaling in growth control and disease. Cell 149:274–293. doi:10.1016/j.cell.2012.03.017
Larsson O, Li S, Issaenko OA et al (2007) Eukaryotic translation initiation factor 4E-induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res 67:6814–6824. doi:10.1158/0008-5472.CAN-07-0752
Lazaris-Karatzas A, Montine K, Sonenberg N (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5’cap. Nature 345:544–547. doi:10.1038/345544a0
Leslie NR, Longy M (2016) Inherited PTEN mutations and the prediction of phenotype. Semin Cell Dev Biol 52:30–38. doi:10.1016/j.semcdb.2016.01.030
Leystra AA, Deming DA, Zahm CD et al (2012) Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res 72:2931–2936. doi:10.1158/0008-5472.CAN-11-4097
Li S, Perlman DM, Peterson MS et al (2004) Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J Biol Chem 279:21312–21317. doi:10.1074/jbc.M312467200
Liang S, Yang N, Pan Y et al (2009) Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PLoS ONE. doi:10.1371/journal.pone.0004295
Lien EC, Lyssiotis CA, Cantley LC (2016) Metabolic reprogramming by the PI3K-Akt-mTOR pathway in cancer. pp 39–72
Liu P, Cheng H, Santiago S et al (2011) Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 17:1116–1120. doi:10.1038/nm.2402
LoRusso PM (2016) Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol 34:3803–3815. doi:10.1200/JCO.2014.59.0018
Lu ZH, Shvartsman MB, Lee AY et al (2010) Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res 70:3287–3298. doi:10.1158/0008-5472.CAN-09-3467
Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307–318. doi:10.1038/nrm2672
Macara IG, Marinetti GV, Balduzzi PC (1984) Transforming protein of avian sarcoma virus UR2 is associated with phosphatidylinositol kinase activity: possible role in tumorigenesis. Proc Natl Acad Sci U S A 81:2728–2732
Maira SM, Finan P, Garcia-Echeverria C (2010) From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr Top Microbiol Immunol 347:209–239. doi:10.1007/82-2010-60
Majumder PK, Febbo PG, Bikoff R et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594–601. doi:10.1038/nm1052
Majumder PK, Yeh JJ, George DJ et al (2003) Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 100:7841–7846. doi:10.1073/pnas.1232229100
Malanga D, Belmonte S, Colelli F et al (2016) AKT1E17 K is oncogenic in mouse lung and cooperates with chemical carcinogens in inducing lung cancer. PLoS ONE 11:e0147334. doi:10.1371/journal.pone.0147334
Malstrom S, Tili E, Kappes D et al (2001) Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc Natl Acad Sci U S A 98:14967–14972. doi:10.1073/pnas.231467698
Mamane Y, Petroulakis E, Martineau Y et al (2007) Epigenetic activation of a subset of mRNAs by elF4E explains its effects on cell proliferation. PLoS ONE. doi:10.1371/journal.pone.0000242
Mamane Y, Petroulakis E, Rong L et al (2004) eIF4E–from translation to transformation. Oncogene 23:3172–3179. doi:10.1038/sj.onc.1207549
Mancini ML, Lien EC, Toker A (2016) Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget. doi:10.18632/oncotarget.8191
Mandelker D, Gabelli SB, Schmidt-Kittler O et al (2009) A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane. Proc Natl Acad Sci U S A 106:16996–17001. doi:10.1073/pnas.0908444106
Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261–1274. doi:10.1016/j.cell.2007.06.009
Manning BD, Tee AR, Logsdon MN et al (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151–162
Mavrakis KJ, Zhu H, Silva RLA et al (2008) Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev 22:2178–2188. doi:10.1101/gad.1690808
Mayer IA, Arteaga CL (2014) The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med 67. doi:10.1146/annurev-med-062913-051343
Mellor P, Furber LAA, Nyarko JNKNK, Anderson DHH (2011) Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking. Biochem J 441:23–37. doi:10.1042/BJ20111164
Mende I, Malstrom S, Tsichlis PN et al (2001) Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 20:4419–4423. doi:10.1038/sj.onc.1204486
Meng L-H, Zheng XS (2015) Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin 36:1163–1169. doi:10.1038/aps.2015.68
Meyer DS, Brinkhaus H, Müller U et al (2011) Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 71:4344–4351. doi:10.1158/0008-5472.CAN-10-3827
Mirza AM, Kohn AD, Roth RA, McMahon M (2000) Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Cell Growth Differ 11:279–292
Moral M, Segrelles C, Lara MF et al (2009) Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma. Cancer Res 69:1099–1108. doi:10.1158/0008-5472.CAN-08-3240
Morita M, Gravel SP, Chénard V et al (2013) MTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab 18:698–711. doi:10.1016/j.cmet.2013.10.001
Morita M, Gravel SP, Hulea L et al (2015) MTOR coordinates protein synthesis, mitochondrial activity. Cell Cycle 14:473–480. doi:10.4161/15384101.2014.991572
Murugan AK, Alzahrani A, Xing M (2013) Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem 288:6511–6521. doi:10.1074/jbc.M112.399485
Nardella C, Carracedo A, Alimonti A et al (2009) Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal 2:ra2. doi:10.1126/scisignal.2000189
Nardella C, Carracedo A, Salmena L, Pandolfi PP (2010) Faithfull modeling of PTEN loss driven diseases in the mouse. Curr Top Microbiol Immunol 347:135–168. doi:10.1007/82-2010-62
Nardella C, Chen Z, Salmena L et al (2008) Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events service Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. 2172–2177. doi:10.1101/gad.1699608
Narita M, Young ARJ, Arakawa S et al (2011) Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science 332:966–970. doi:10.1126/science.1205407
Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314–10319. doi:10.1073/pnas.171076798
Ni J, Liu Q, Xie S et al (2012) Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov 2:425–433. doi:10.1158/2159-8290.CD-12-0003
Ohne Y, Terunao Takahara T, Maeda T (2009) Evaluation of mTOR function by a gain-of-function approach. Cell Cycle 8:573–579
Onda H, Lueck A, Marks PW et al (1999) Tsc2(±) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 104:687–695. doi:10.1172/JCI7319
Ooms LM, Binge LC, Davies EM et al (2015) The inositol polyphosphate 5-phosphatase PIPP regulates AKT1-dependent breast cancer growth and metastasis. Cancer Cell 28:155–169. doi:10.1016/j.ccell.2015.07.003
Papa A, Wan L, Bonora M et al (2014) Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. Cell 157:595–610. doi:10.1016/j.cell.2014.03.027
Parsons DW, Wang T-L, Samuels Y et al (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436:792. doi:10.1038/436792a
Pérez-Mancera PA, Young ARJ, Narita M (2014) Inside and out: the activities of senescence in cancer. Nat Rev Cancer 14:547–558. doi:10.1038/nrc3773
Peterson TR, Sengupta SS, Harris TE et al (2011) MTOR complex 1 regulates lipin 1 localization to control the srebp pathway. Cell 146:408–420. doi:10.1016/j.cell.2011.06.034
Podsypanina K, Ellenson LH, Nemes A et al (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 96:1563–1568. doi:10.1073/pnas.96.4.1563
Podsypanina K, Lee RT, Politis C et al (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten± mice. Proc Natl Acad Sci U S A 98:10320–10325. doi:10.1073/pnas.171060098
Porstmann T, Santos CR, Griffiths B et al (2008) SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 8:224–236. doi:10.1016/j.cmet.2008.07.007
Posor Y, Eichhorn-Gruenig M, Puchkov D et al (2013) Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate. Nature 499:233–237. doi:10.1038/nature12360
Potter CJ, Pedraza LG, Xu T (2002) Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4:658–665. doi:10.1038/ncb840
Rijal S, Fleming S, Cummings N et al (2015) Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML. Blood 125:2815–2824. doi:10.1182/blood-2014-09-603555
Robinson G, Parker M, Kranenburg TA et al (2012a) Novel mutations target distinct subgroups of medulloblastoma. Nature 488:43–48. doi:10.1038/nature11213.Novel
Robinson G, Parker M, Kranenburg T, Lu C (2012b) Novel mutations target distinct subgroups of medulloblastoma. Nature 488:43–48. doi:10.1038/nature11213.Novel
Robitaille AM, Christen S, Shimobayashi M et al (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339:1320–1323. doi:10.1126/science.1228771
Ruggero D, Montanaro L, Ma L et al (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10:484–486. doi:10.1038/nm1042
Samuels Y, Waldman T (2010) Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 347:21–41. doi:10.1007/82-2010-68
Samuels Y, Wang Z, Bardelli A et al (2004) Brevia: high frequency of mutations of the PIK3Ca gene in human cancers. Science 304:554. doi:10.1126/science.1096502
Sancak Y, Thoreen CC, Peterson TR et al (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25:903–915. doi:10.1016/j.molcel.2007.03.003
Sander S, Calado DP, Srinivasan L et al (2012) Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22:167–179. doi:10.1016/j.ccr.2012.06.012
Sasaki H, Okuda K, Kawano O et al (2008) AKT1 and AKT2 mutations in lung cancer in a Japanese population. Mol Med Rep. doi:10.3892/mmr-00000009
Sato T, Nakashima A, Guo L et al (2010) Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29:2746–2752. doi:10.1038/onc.2010.28
Schmit F, Utermark T, Zhang S et al (2014) PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 111:6395–6400. doi:10.1073/pnas.1323004111
Segrelles C, Lu J, Hammann B et al (2007) Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis. Cancer Res 67:10879–10888. doi:10.1158/0008-5472.CAN-07-2564
Shaw RJ, Bardeesy N, Manning BD et al (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91–99. doi:10.1016/j.ccr.2004.06.007
Siddiqui N, Sonenberg N (2015) Signalling to eIF4E in cancer. Biochem Soc Trans 43:763–772. doi:10.1042/BST20150126
Simonsen A, Tooze SA (2009) Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes. J Cell Biol 186:773–782. doi:10.1083/jcb.200907014
Skeen JE, Bhaskar PT, Chen CC et al (2006) Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10:269–280. doi:10.1016/j.ccr.2006.08.022
Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13:283–296. doi:10.1038/nrm3330
Stambolic V, Tsao MS, Macpherson D et al (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten(±) mice. Cancer Res 60:3605–3611
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084–6091. doi:10.1158/0008-5472.CAN-07-6854
Stephens L, Hawkins P (2013) More paths to PI3Kγ PLoS Biol 11:1–3. doi:10.1371/journal.pbio.1001594
Stephens PJ, Tarpey PS, Davies H et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400–404. doi:10.1038/nature11017
Stine ZE, Walton ZE, Altman BJ et al (2015) MYC, metabolism, and cancer. Cancer Discov 5:1024–1039
Sugimoto Y, Whitman M, Cantley LC, Erikson RL (1984) Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci U S A 81:2117–2121
Sun M, Hillmann P, Hofmann BT et al (2010) Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α. Proc Natl Acad Sci U S A 107:15547–15552. doi:10.1073/pnas.1009652107
Sun M, Wang G, Paciga JE et al (2001) AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159:431–437. doi:10.1016/S0002-9440(10)61714-2
Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15:7–24. doi:10.1038/nrc3860
Tikoo A, Roh V, Montgomery KG et al (2012) Physiological levels of Pik3caH1047R mutation in the mouse mammary gland results in ductal hyperplasia and formation of ER??-positive tumors. PLoS ONE 7:1–13. doi:10.1371/journal.pone.0036924
Toker A (2012) Achieving specificity in Akt signaling in cancer Alex. Adv Biol Regul 52:78–87. doi:10.1016/j.surg.2006.10.010.Use
Toker A, Marmiroli S (2014) Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul 55:28–38
Topisirovic I, Ruiz-Gutierrez M, Borden KLB (2004) Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 64:8639–8642. doi:10.1158/0008-5472.CAN-04-2677
Trejo CL, Green S, Marsh V et al (2013) Mutationally activated PIK3CAH1047R cooperates with BRAF V600E to promote lung cancer progression. Cancer Res 73:6448–6461. doi:10.1158/0008-5472.CAN-13-0681
Truitt MLL, Conn CSS, Shi Z et al (2015) Differential requirements for eIF4E dose in normal development and cancer. Cell 162:59–71. doi:10.1016/j.cell.2015.05.049
Turner KM, Sun Y, Ji P et al (2015) Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci U S A 112:3421–3426. doi:10.1073/pnas.1414573112
Utani A (2010) Laminin α3 chain-derived peptide promotes keratinocyte migration and wound closure: clustering of syndecan-4 and integrin β1. Seikagaku 82:327–331. doi:10.1091/mbc.E08
Utermark T, Rao T, Cheng H et al (2012) The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev 26:1573–1586. doi:10.1101/gad.191973.112
Van Keymeulen A, Lee MY, Ousset M et al (2015) Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 525:119–123. doi:10.1038/nature14665
Vander Haar E, Lee S-I, Bandhakavi S et al (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9:316–323. doi:10.1038/ncb1547
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033. doi:10.1126/science.1160809
Vanhaesebroeck B, Leevers SJ, Panayotou G et al (1997) Phosphoinositide 3-kinases: A conserved family of signal transducers. Trends Biochem Sci 22:267–272
Vasudevan KM, Garraway LA (2010) AKT signaling in physiology and disease. Curr Top Microbiol Immunol 347:105–133. doi:10.1007/82_2010_66
Vivanco I, Sawyers C (2002) The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat Rev - Cancer 2:489–501. doi:10.1038/nrc839
Vogt PK (2012) Retroviral oncogenes: a historical primer. Nat Rev Cancer 12:639–648. doi:10.1038/nrc3320
Vogt PK, Hart JR, Gymnopoulos M et al (2010) Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol 347:79–104. doi:10.1007/82-2010-80
Walker EH, Perisic O, Ried C et al (1999) Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402:313–320. doi:10.1038/46319
Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21:297–308. doi:10.1016/j.ccr.2012.02.014
Wee S, Wiederschain D, Maria S-M et al (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 105:13057–13062. doi:10.1073/pnas.0802655105
Wendel H-G, De Stanchina E, Fridman JS et al (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332–337. doi:10.1038/nature02369
Wendel HG, Silva RLA, Malina A et al (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21:3232–3237. doi:10.1101/gad.1604407
Whitman M, Downes CP, Keeler M et al (1988) Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332:644–646
Wu CYC, Carpenter ES, Takeuchi KK et al (2014a) PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology 147:1405–1416.e7. doi:10.1053/j.gastro.2014.08.032
Wu H, Shekar SC, Flinn RJ et al (2009) Regulation of class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants. Proc Natl Acad Sci U S A 106:20258–20263. doi:10.1073/pnas.0902369106
Wu R, Baker SJ, Hu TC et al (2013) Type i to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol 182:1391–1399. doi:10.1016/j.ajpath.2012.12.031
Wu R, Hu TC, Rehemtulla A et al (2011) Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 17:7359–7372. doi:10.1158/1078-0432.CCR-11-1388
Wu Y, Kim J, Elshimali Y et al (2014b) Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice. BMC Cancer 14:266. doi:10.1186/1471-2407-14-266
Xu P-Z, Chen M-L, Jeon S-M et al (2012) The effect Akt2 deletion on tumor development in Pten(±) mice. Oncogene 31:518–526. doi:10.1038/onc.2011.243
Yamaguchi H, Kawazu M, Yasuda T et al (2015) Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer. Cancer Sci 106:1687–1692. doi:10.1111/cas.12828
Yang J, Kalogerou M, Samsel PA et al (2014) Renal tumours in a Tsc2(±) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin. Oncogene: 1–10. doi:10.1038/onc.2014.17
Yang Q, Modi P, Newcomb T et al (2015) Idelalisib: first-in-class PI3K δ inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res 21:1537–1542. doi:10.1158/1078-0432.CCR-14-2034
Yap TA, Bjerke L, Clarke PA, Workman P (2015) Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol 23:98–107. doi:10.1016/j.coph.2015.05.016
Young CD, Nolte EC, Lewis A et al (2008) Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Res 10:R70. doi:10.1186/bcr2132
Yuan W, Stawiski E, Janakiraman V et al (2013) Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 32:318–326. doi:10.1038/onc.2012.53
Yuzugullu H, Baitsch L, Von T et al (2015) A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nat Commun 6:8501. doi:10.1038/ncomms9501
Zaytseva YY, Valentino JD, Gulhati P, Mark Evers B (2012) MTOR inhibitors in cancer therapy. Cancer Lett 319:1–7. doi:10.1016/j.canlet.2012.01.005
Zhai Y, Kuick R, Tipton C et al (2016) Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival. J Pathol 238:21–30. doi:10.1002/path.4599
Zhao JJ, Liu Z, Wang L et al (2005) The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 102:18443–18448. doi:10.1073/pnas.0508988102
Zhao L, Vogt PK (2008a) Class I PI3K in oncogenic cellular transformation. Oncogene 27:5486–5496. doi:10.1038/onc.2008.244
Zhao L, Vogt PK (2008b) Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci 105:2652–2657. doi:10.1073/pnas.0712169105
Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21–35. doi:10.1038/nrm3025
Acknowledgments
The authors thank Tatsuhiro Sato for critical reading of the manuscript. M. Aoki would like to thank Peter K. Vogt for his excellent mentorship during my years in his laboratory and for continuous encouragement.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Aoki, M., Fujishita, T. (2017). Oncogenic Roles of the PI3K/AKT/mTOR Axis. In: Hunter, E., Bister, K. (eds) Viruses, Genes, and Cancer. Current Topics in Microbiology and Immunology, vol 407. Springer, Cham. https://doi.org/10.1007/82_2017_6
Download citation
DOI: https://doi.org/10.1007/82_2017_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-61803-6
Online ISBN: 978-3-319-61804-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)